Gottlieb's Proposals Provide Possible Insight Into Upcoming Agency Reforms

President Donald Trump's allegation Tuesday (Feb. 29) that FDA's approval process impedes patient access to drugs aligns closely with criticisms levied for years by a top contender for the FDA commissioner position, Scott Gottlieb. The former FDA deputy commissioner and current resident fellow at the American Enterprise Institute has publicly criticized FDA's handling of rare diseases drug reviews, frequently calling for greater flexibility and less focus on drug efficacy. Gottlieb has also laid out grander FDA reform visions including restructuring...